52 related articles for article (PubMed ID: 15778428)
1. Population pharmacokinetics of efalizumab (humanized monoclonal anti-CD11a antibody) following long-term subcutaneous weekly dosing in psoriasis subjects.
Sun YN; Lu JF; Joshi A; Compton P; Kwon P; Bruno RA
J Clin Pharmacol; 2005 Apr; 45(4):468-76. PubMed ID: 15778428
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetic analysis of peficitinib in patients with rheumatoid arthritis.
Toyoshima J; Shibata M; Kaibara A; Kaneko Y; Izutsu H; Nishimura T
Br J Clin Pharmacol; 2021 Apr; 87(4):2014-2022. PubMed ID: 33068028
[TBL] [Abstract][Full Text] [Related]
3. Understanding Inter-Individual Variability in Monoclonal Antibody Disposition.
Thomas VA; Balthasar JP
Antibodies (Basel); 2019 Dec; 8(4):. PubMed ID: 31817205
[TBL] [Abstract][Full Text] [Related]
4. A new era for migraine: Pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody.
Kielbasa W; Helton DL
Cephalalgia; 2019 Sep; 39(10):1284-1297. PubMed ID: 30917684
[TBL] [Abstract][Full Text] [Related]
5. Influence of Antigen Mass on the Pharmacokinetics of Therapeutic Antibodies in Humans.
Ternant D; Azzopardi N; Raoul W; Bejan-Angoulvant T; Paintaud G
Clin Pharmacokinet; 2019 Feb; 58(2):169-187. PubMed ID: 29802542
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics and exposure-response modeling and simulation for evolocumab in healthy volunteers and patients with hypercholesterolemia.
Kuchimanchi M; Grover A; Emery MG; Somaratne R; Wasserman SM; Gibbs JP; Doshi S
J Pharmacokinet Pharmacodyn; 2018 Jun; 45(3):505-522. PubMed ID: 29736889
[TBL] [Abstract][Full Text] [Related]
7. Potential Sources of Inter-Subject Variability in Monoclonal Antibody Pharmacokinetics.
Gill KL; Machavaram KK; Rose RH; Chetty M
Clin Pharmacokinet; 2016 Jul; 55(7):789-805. PubMed ID: 26818483
[TBL] [Abstract][Full Text] [Related]
8. Influence of tumour burden on trastuzumab pharmacokinetics in HER2 positive non-metastatic breast cancer.
Bernadou G; Campone M; Merlin JL; Gouilleux-Gruart V; Bachelot T; Lokiec F; Rezai K; Arnedos M; Diéras V; Jimenez M; Paintaud G; Ternant D
Br J Clin Pharmacol; 2016 May; 81(5):941-8. PubMed ID: 26714164
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics of tanezumab in phase 3 clinical trials for osteoarthritis pain.
Jonsson EN; Xie R; Marshall SF; Arends RH
Br J Clin Pharmacol; 2016 Apr; 81(4):688-99. PubMed ID: 26613544
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.
Dostalek M; Gardner I; Gurbaxani BM; Rose RH; Chetty M
Clin Pharmacokinet; 2013 Feb; 52(2):83-124. PubMed ID: 23299465
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics of farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer.
Farrell C; Schweizer C; Wustner J; Weil S; Namiki M; Nakano T; Nakai K; Phillips MD
Cancer Chemother Pharmacol; 2012 Nov; 70(5):727-34. PubMed ID: 22955257
[TBL] [Abstract][Full Text] [Related]
12. A guide to rational dosing of monoclonal antibodies.
Bai S; Jorga K; Xin Y; Jin D; Zheng Y; Damico-Beyer LA; Gupta M; Tang M; Allison DE; Lu D; Zhang Y; Joshi A; Dresser MJ
Clin Pharmacokinet; 2012 Feb; 51(2):119-35. PubMed ID: 22257150
[TBL] [Abstract][Full Text] [Related]
13. Model-based determination of abatacept exposure in support of the recommended dose for Japanese rheumatoid arthritis patients.
Hasegawa M; Imai Y; Hiraoka M; Ito K; Roy A
J Pharmacokinet Pharmacodyn; 2011 Dec; 38(6):803-32. PubMed ID: 22002809
[TBL] [Abstract][Full Text] [Related]
14. Population PK and IgE pharmacodynamic analysis of a fully human monoclonal antibody against IL4 receptor.
Kakkar T; Sung C; Gibiansky L; Vu T; Narayanan A; Lin SL; Vincent M; Banfield C; Colbert A; Hoofring S; Starcevic M; Ma P
Pharm Res; 2011 Oct; 28(10):2530-42. PubMed ID: 21604075
[TBL] [Abstract][Full Text] [Related]
15. Quantitative prediction of human pharmacokinetics for monoclonal antibodies: retrospective analysis of monkey as a single species for first-in-human prediction.
Dong JQ; Salinger DH; Endres CJ; Gibbs JP; Hsu CP; Stouch BJ; Hurh E; Gibbs MA
Clin Pharmacokinet; 2011 Feb; 50(2):131-42. PubMed ID: 21241072
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics of therapeutic monoclonal antibodies.
Dirks NL; Meibohm B
Clin Pharmacokinet; 2010 Oct; 49(10):633-59. PubMed ID: 20818831
[TBL] [Abstract][Full Text] [Related]
17. Application of quantitative pharmacology in development of therapeutic monoclonal antibodies.
Tabrizi M; Funelas C; Suria H
AAPS J; 2010 Dec; 12(4):592-601. PubMed ID: 20652780
[TBL] [Abstract][Full Text] [Related]
18. Clinical pharmacokinetics of therapeutic monoclonal antibodies.
Keizer RJ; Huitema AD; Schellens JH; Beijnen JH
Clin Pharmacokinet; 2010 Aug; 49(8):493-507. PubMed ID: 20608753
[TBL] [Abstract][Full Text] [Related]
19. Long-term multiple-dose pharmacokinetics of human monoclonal antibodies (MAbs) against human immunodeficiency virus type 1 envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5).
Joos B; Trkola A; Kuster H; Aceto L; Fischer M; Stiegler G; Armbruster C; Vcelar B; Katinger H; Günthard HF
Antimicrob Agents Chemother; 2006 May; 50(5):1773-9. PubMed ID: 16641449
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
